SecBot SecBot
DEFA14A ·Filed Jun 16, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001104659-26-074562
Proxy solicitation materials
Actionable Insight ▲ Bullish

The HSR clearance significantly de-risks the merger timeline. The next catalyst is the July 8 stockholder vote; monitor for any dissident opposition or competing bids. If approved, the stock should converge toward the merger consideration.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$3.17
T+0 close · Jun 16, 2026 · via day close
Latest settled
−0.63%
T+5 · $3.15
Vs SPY
+0.41%
α at T+5
Next horizon
T+20
due 4mo ago
  1. T+0 · Jun 17 $3.17entry
  2. T+1 · 5mo ago −0.63%α −1.41% · $3.15
  3. T+5 · 5mo ago −0.63%α +0.41% · $3.15
  4. T+20 · due 4mo ago Pending
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion Therapeutics disclosed that the Hart-Scott-Rodino waiting period for its pending merger with an affiliate of ArchiMed SAS expired on June 15, 2026, removing a key regulatory condition. The special stockholder meeting to vote on the merger is scheduled for July 8, 2026, and the deal remains subject to stockholder approval and other customary closing conditions.

Key Financial Metrics

Vote
merger approval
Meeting
2026-07-08

Key Facts

  • HSR waiting period for the ArchiMed merger expired on June 15, 2026.
  • Special stockholder meeting to vote on the merger is set for July 8, 2026.
  • Merger agreement was entered into on May 1, 2026, with Essence Parent Inc. (ArchiMed affiliate).
  • Closing remains subject to stockholder adoption and other customary conditions.

Financial Impact

Not specified

merger completion

Risk Factors

  • Stockholder approval is not guaranteed; failure to adopt would terminate the deal.
  • Other closing conditions (e.g., no material adverse change) could still block completion.
  • Potential litigation or regulatory delays beyond HSR.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-074562
Document: 0001104659-26-074562-index-headers.html0001104659-26-074562
Document: 0001104659-26-074562-index.html0001104659-26-074562
Document: 0001104659-26-074562.txt0001104659-26-074562

Track record

21 reports on ESPR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Viewing Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026